188 related articles for article (PubMed ID: 38265263)
1. FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling.
Kanaoka D; Yamada M; Yokoyama H; Nishino S; Kunimura N; Satoyoshi H; Wakabayashi S; Urabe K; Ishii T; Nakanishi M
Cancer Res Commun; 2024 Feb; 4(2):312-327. PubMed ID: 38265263
[TBL] [Abstract][Full Text] [Related]
2. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.
Bidère N; Ngo VN; Lee J; Collins C; Zheng L; Wan F; Davis RE; Lenz G; Anderson DE; Arnoult D; Vazquez A; Sakai K; Zhang J; Meng Z; Veenstra TD; Staudt LM; Lenardo MJ
Nature; 2009 Mar; 458(7234):92-6. PubMed ID: 19118383
[TBL] [Abstract][Full Text] [Related]
3. Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216.
Teng M; Lu W; Donovan KA; Sun J; Krupnick NM; Nowak RP; Li YD; Sperling AS; Zhang T; Ebert BL; Fischer ES; Gray NS
J Med Chem; 2022 Jan; 65(1):747-756. PubMed ID: 34965125
[TBL] [Abstract][Full Text] [Related]
4. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
5. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
8. Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation.
Carvalho G; Le Guelte A; Demian C; Vazquez A; Gavard J; Bidère N
J Cell Sci; 2010 Jul; 123(Pt 14):2375-80. PubMed ID: 20551178
[TBL] [Abstract][Full Text] [Related]
9. Design and Development of IKZF2 and CK1α Dual Degraders.
Miyamoto DK; Curnutt NM; Park SM; Stavropoulos A; Kharas MG; Woo CM
J Med Chem; 2023 Dec; 66(24):16953-16979. PubMed ID: 38085607
[TBL] [Abstract][Full Text] [Related]
10. MDMX inhibits casein kinase 1α activity and stimulates Wnt signaling.
Huang Q; Chen L; Schonbrunn E; Chen J
EMBO J; 2020 Jul; 39(14):e104410. PubMed ID: 32511789
[TBL] [Abstract][Full Text] [Related]
11. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
[TBL] [Abstract][Full Text] [Related]
12. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
Song C; Gowda C; Pan X; Ding Y; Tong Y; Tan BH; Wang H; Muthusami S; Ge Z; Sachdev M; Amin SG; Desai D; Gowda K; Gowda R; Robertson GP; Schjerven H; Muschen M; Payne KJ; Dovat S
Blood; 2015 Oct; 126(15):1813-22. PubMed ID: 26219304
[TBL] [Abstract][Full Text] [Related]
13. Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.
Park SM; Miyamoto DK; Han GYQ; Chan M; Curnutt NM; Tran NL; Velleca A; Kim JH; Schurer A; Chang K; Xu W; Kharas MG; Woo CM
Cancer Cell; 2023 Apr; 41(4):726-739.e11. PubMed ID: 36898380
[TBL] [Abstract][Full Text] [Related]
14. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
[TBL] [Abstract][Full Text] [Related]
15. Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth.
Huart AS; MacLaine NJ; Narayan V; Hupp TR
PLoS One; 2012; 7(8):e43391. PubMed ID: 22916255
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Manni S; Carrino M; Manzoni M; Gianesin K; Nunes SC; Costacurta M; Tubi LQ; Macaccaro P; Taiana E; Cabrelle A; Barilà G; Martines A; Zambello R; Bonaldi L; Trentin L; Neri A; Semenzato G; Piazza F
Oncotarget; 2017 Feb; 8(9):14604-14619. PubMed ID: 28099937
[TBL] [Abstract][Full Text] [Related]
17. Regulation of p53-MDMX interaction by casein kinase 1 alpha.
Chen L; Li C; Pan Y; Chen J
Mol Cell Biol; 2005 Aug; 25(15):6509-20. PubMed ID: 16024788
[TBL] [Abstract][Full Text] [Related]
18. Casein kinase 1α regulates murine spermatogenesis via p53-Sox3 signaling.
Lu C; Zhang D; Zhang J; Li L; Qiu J; Gou K; Cui S
Development; 2022 Jul; 149(13):. PubMed ID: 35698877
[TBL] [Abstract][Full Text] [Related]
19. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
20. Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis.
Sinnberg T; Menzel M; Kaesler S; Biedermann T; Sauer B; Nahnsen S; Schwarz M; Garbe C; Schittek B
Cancer Res; 2010 Sep; 70(17):6999-7009. PubMed ID: 20699366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
